{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:38:58Z","timestamp":1767983938287,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board (SERB), Government of India","doi-asserted-by":"publisher","award":["ECR\/2017\/000293"],"award-info":[{"award-number":["ECR\/2017\/000293"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00277-021-04574-0","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:02:15Z","timestamp":1624399335000},"page":"2031-2041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort"],"prefix":"10.1007","volume":"100","author":[{"given":"Harpreet","family":"Virk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parveen Lata","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diksha Dev","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Updesh Singh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka Rani","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4154","authenticated-orcid":false,"given":"Sreejesh","family":"Sreedharanunni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"4574_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","volume":"147","author":"S Konoplev","year":"2017","unstructured":"Konoplev S, Lu X, Konopleva M et al (2017) CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: a single-institution experience. Am J Clin Pathol 147:357\u2013363. https:\/\/doi.org\/10.1093\/ajcp\/aqx005","journal-title":"Am J Clin Pathol"},{"key":"4574_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","volume":"41","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Collins-Underwood JR, Phillips LAA et al (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243\u20131246. https:\/\/doi.org\/10.1038\/ng.469","journal-title":"Nat Genet"},{"key":"4574_CR3","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.3324\/haematol.2014.114447","volume":"100","author":"C Bugarin","year":"2015","unstructured":"Bugarin C, Sarno J, Palmi C et al (2015) Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 100:e229-232. https:\/\/doi.org\/10.3324\/haematol.2014.114447","journal-title":"Haematologica"},{"key":"4574_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.leukres.2015.11.018","volume":"41","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, Brugnoletti F, Messina M et al (2016) CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res 41:36\u201342. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.018","journal-title":"Leuk Res"},{"key":"4574_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","volume":"4","author":"RC Harvey","year":"2020","unstructured":"Harvey RC, Tasian SK (2020) Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv 4:218\u2013228. https:\/\/doi.org\/10.1182\/bloodadvances.2019000163","journal-title":"Blood Adv"},{"key":"4574_CR6","doi-asserted-by":"publisher","unstructured":"Roederer M (2002) Compensation in flow cytometry. Curr Protoc Cytom Chapter 1:Unit 1.14. https:\/\/doi.org\/10.1002\/0471142956.cy0114s22","DOI":"10.1002\/0471142956.cy0114s22"},{"key":"4574_CR7","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1093\/bioinformatics\/btu575","volume":"30","author":"K Feher","year":"2014","unstructured":"Feher K, Kirsch J, Radbruch A et al (2014) Cell population identification using fluorescence-minus-one controls with a one-class classifying algorithm. Bioinformatics 30:3372\u20133378. https:\/\/doi.org\/10.1093\/bioinformatics\/btu575","journal-title":"Bioinformatics"},{"key":"4574_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1006\/bbrc.2001.4432","volume":"281","author":"W Zhang","year":"2001","unstructured":"Zhang W, Wang J, Wang Q et al (2001) Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes. Biochem Biophys Res Commun 281:878\u2013883. https:\/\/doi.org\/10.1006\/bbrc.2001.4432","journal-title":"Biochem Biophys Res Commun"},{"key":"4574_CR9","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1097\/MPH.0000000000001892","volume":"43","author":"P Sharma","year":"2021","unstructured":"Sharma P, Rana S, Sreedharanunni S et al (2021) (2020) An evaluation of a fluorescence in situ hybridization strategy using air-dried blood and bone-marrow smears in the risk stratification of pediatric B-lineage acute lymphoblastic leukemia in resource-limited settings. J Pediatr Hematol Oncol 43:e481\u2013e485. https:\/\/doi.org\/10.1097\/MPH.0000000000001892 (PMID: 32769569)","journal-title":"J Pediatr Hematol Oncol"},{"key":"4574_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cyto.a.22803","volume":"89","author":"P Tembhare","year":"2016","unstructured":"Tembhare P, Badrinath Y, Ghogale S et al (2016) A novel and easy FxCycleTM violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A 89:281\u2013291. https:\/\/doi.org\/10.1002\/cyto.a.22803","journal-title":"Cytometry A"},{"key":"4574_CR11","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1002\/cpcy.15","volume":"80","author":"P Tembhare","year":"2017","unstructured":"Tembhare P, Badrinath Y, Ghogale S, Subramanian PG (2017) Method for DNA ploidy analysis along with immunophenotyping for rare populations in a sample using FxCycle Violet. Curr Protoc Cytom 80:6381\u201363815. https:\/\/doi.org\/10.1002\/cpcy.15","journal-title":"Curr Protoc Cytom"},{"key":"4574_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/cyto.b.21765","volume":"96","author":"N Gupta","year":"2019","unstructured":"Gupta N, Parihar M, Banerjee S et al (2019) FxCycleTM based ploidy correlates with cytogenetic ploidy in B-cell acute lymphoblastic leukemia and is able to detect the aneuploid minimal residual disease clone. Cytometry B Clin Cytom 96:359\u2013367. https:\/\/doi.org\/10.1002\/cyto.b.21765","journal-title":"Cytometry B Clin Cytom"},{"key":"4574_CR13","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.phoj.2018.11.052","volume":"3","author":"P Roy","year":"2018","unstructured":"Roy P, Narula G, Arora B et al (2018) Implementation of risk adapted therapeutic strategy for childhood acute lymphoblastic leukaemia \u2013 interim report of the pilot InPOG-ALL-15-01 study. Pediatric Hematology Oncology Journal 3:S19. https:\/\/doi.org\/10.1016\/j.phoj.2018.11.052","journal-title":"Pediatric Hematology Oncology Journal"},{"key":"4574_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/10428190701343255","volume":"48","author":"P Malhotra","year":"2007","unstructured":"Malhotra P, Varma S, Varma N et al (2007) Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting. Leuk Lymphoma 48:1173\u20131178. https:\/\/doi.org\/10.1080\/10428190701343255","journal-title":"Leuk Lymphoma"},{"key":"4574_CR15","first-page":"1065","volume":"53","author":"K Bommannan","year":"2016","unstructured":"Bommannan K, Singh Sachdeva MU, Varma N et al (2016) Role of mid-induction peripheral blood minimal residual disease detection in pediatric B-lineage acute lymphoblastic leukemia. Indian Pediatr 53:1065\u20131068","journal-title":"Indian Pediatr"},{"key":"4574_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cyto.b.21831","volume":"98","author":"PR Tembhare","year":"2020","unstructured":"Tembhare PR, Subramanian Pg PG, Ghogale S et al (2020) A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: a study of 622 patients. Cytometry B Clin Cytom 98:57\u201367. https:\/\/doi.org\/10.1002\/cyto.b.21831","journal-title":"Cytometry B Clin Cytom"},{"key":"4574_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21951(Onlineaheadofprint)","author":"G Chatterjee","year":"2020","unstructured":"Chatterjee G, Sriram H, Ghogale S et al (2020) Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: a critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia. Cytometry B Clin Cytom. https:\/\/doi.org\/10.1002\/cyto.b.21951(Onlineaheadofprint)","journal-title":"Cytometry B Clin Cytom"},{"key":"4574_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.seminhematol.2008.09.001","volume":"46","author":"D Campana","year":"2009","unstructured":"Campana D (2009) MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKEMIA. Semin Hematol 46:100\u2013106. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.09.001","journal-title":"Semin Hematol"},{"key":"4574_CR19","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow P, Key L, Chen X et al (2010) Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 115:4657\u20134663. https:\/\/doi.org\/10.1182\/blood-2009-11-253435","journal-title":"Blood"},{"key":"4574_CR20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/pbc.24571","volume":"60","author":"Y Yamashita","year":"2013","unstructured":"Yamashita Y, Shimada A, Yamada T et al (2013) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 60:1587\u20131592. https:\/\/doi.org\/10.1002\/pbc.24571","journal-title":"Pediatr Blood Cancer"},{"key":"4574_CR21","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","volume":"115","author":"G Cario","year":"2010","unstructured":"Cario G, Zimmermann M, Romey R et al (2010) Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non\u2013high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393\u20135397. https:\/\/doi.org\/10.1182\/blood-2009-11-256131","journal-title":"Blood"},{"key":"4574_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2010","unstructured":"Yoda A, Yoda Y, Chiaretti S et al (2010) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 107:252\u2013257. https:\/\/doi.org\/10.1073\/pnas.0911726107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4574_CR23","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","volume":"119","author":"I-M Chen","year":"2012","unstructured":"Chen I-M, Harvey RC, Mullighan CG et al (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study. Blood 119:3512\u20133522. https:\/\/doi.org\/10.1182\/blood-2011-11-394221","journal-title":"Blood"},{"key":"4574_CR24","doi-asserted-by":"publisher","first-page":"25971","DOI":"10.18632\/oncotarget.25411","volume":"9","author":"A Pastorczak","year":"2018","unstructured":"Pastorczak A, Sedek L, Braun M et al (2018) Surface expression of cytokine receptor-like factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions. Oncotarget 9:25971\u201325982. https:\/\/doi.org\/10.18632\/oncotarget.25411","journal-title":"Oncotarget"},{"key":"4574_CR25","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/leu.2012.101","volume":"26","author":"C Palmi","year":"2012","unstructured":"Palmi C, Vendramini E, Silvestri D et al (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26:2245\u20132253. https:\/\/doi.org\/10.1038\/leu.2012.101","journal-title":"Leukemia"},{"key":"4574_CR26","doi-asserted-by":"publisher","first-page":"49722","DOI":"10.18632\/oncotarget.10437","volume":"7","author":"Z Ge","year":"2016","unstructured":"Ge Z, Gu Y, Zhao G et al (2016) High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget 7:49722\u201349732. https:\/\/doi.org\/10.18632\/oncotarget.10437","journal-title":"Oncotarget"},{"key":"4574_CR27","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.3324\/haematol.2016.161000","volume":"102","author":"N Jain","year":"2017","unstructured":"Jain N, Lu X, Daver N et al (2017) Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102:e514\u2013e517. https:\/\/doi.org\/10.3324\/haematol.2016.161000","journal-title":"Haematologica"},{"key":"4574_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","volume":"117","author":"HM Ensor","year":"2011","unstructured":"Ensor HM, Schwab C, Russell LJ et al (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117:2129\u20132136. https:\/\/doi.org\/10.1182\/blood-2010-07-297135","journal-title":"Blood"},{"key":"4574_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-134327","volume":"136","author":"SK Tasian","year":"2020","unstructured":"Tasian SK, Dai Y, Devidas M et al (2020) Outcomes of patients with CRLF2-overexpressing acute lymphoblastic leukemia without down syndrome: a report from the Children\u2019s Oncology Group. Blood 136:45\u201346. https:\/\/doi.org\/10.1182\/blood-2020-134327","journal-title":"Blood"},{"key":"4574_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.28","volume":"6","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kiyokawa N, Kato M et al (2016) Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J 6:e419. https:\/\/doi.org\/10.1038\/bcj.2016.28","journal-title":"Blood Cancer J"},{"key":"4574_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5858\/arpa.2019-0194-RA","volume":"144","author":"S Jain","year":"2019","unstructured":"Jain S, Abraham A (2019) BCR-ABL1\u2013like B-acute lymphoblastic leukemia\/lymphoma: a comprehensive review. Arch Pathol Lab Med 144:150\u2013155. https:\/\/doi.org\/10.5858\/arpa.2019-0194-RA","journal-title":"Arch Pathol Lab Med"},{"key":"4574_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1929964","author":"P Sharma","year":"2021","unstructured":"Sharma P, Rana S, Virk H et al (2021) The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2021.1929964","journal-title":"Leuk Lymphoma"},{"key":"4574_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24342","author":"H Khenine","year":"2021","unstructured":"Khenine H, Waeckel L, Seghrouchni F et al (2021) Fluorescent energy transfer causing misleading signal in multicolor flow cytometry. Cytometry A. https:\/\/doi.org\/10.1002\/cyto.a.24342","journal-title":"Cytometry A"},{"key":"4574_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cyto.b.20485","volume":"76","author":"R Hulspas","year":"2009","unstructured":"Hulspas R, O\u2019Gorman MRG, Wood BL et al (2009) Considerations for the control of background fluorescence in clinical flow cytometry. Cytometry B Clin Cytom 76:355\u2013364. https:\/\/doi.org\/10.1002\/cyto.b.20485","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04574-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:11:32Z","timestamp":1626412292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04574-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4574"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04574-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The research was carried out according to the Institutional ethics guidelines after obtaining the approval of the extramural research ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}